Literature DB >> 12968220

[Liposuction of arm lymphoedema].

H Brorson1.   

Abstract

Breast cancer is the most common disease in women, and up to 38 % develop lymphoedema of the arm following mastectomy, standard axillary node dissection and postoperative irradiation. Limb reductions have been reported utilising various conservative therapies such as manual lymph drainage and pressure therapy. Some patients with long-standing pronounced lymphoedema do not respond to these conservative treatments because slow or absent lymph flow causes the formation of excess subcutaneous adipose tissue. Previous surgical regimes utilising bridging procedures, total excision with skin grafting or reduction plasty seldom achieved acceptable cosmetic and functional results. Microsurgical reconstruction involving lympho-venous shunts or transplantation of lymph vessels has also been investigated. Although attractive in concept, the common failure of microsurgery to provide complete reduction is due to the persistence of newly formed subcutaneous adipose tissue which is not removed in patients with chronic non-pitting lymphoedema. Liposuction removes the hypertrophied adipose tissue and is a prerequisite to achieve complete reduction. The new equilibrium is maintained through constant (24-hour) use of compression garments postoperatively. Long-term follow-up (seven years) does not show any recurrence of the oedema.

Entities:  

Mesh:

Year:  2003        PMID: 12968220     DOI: 10.1055/s-2003-42128

Source DB:  PubMed          Journal:  Handchir Mikrochir Plast Chir        ISSN: 0722-1819            Impact factor:   1.018


  2 in total

1.  [Therapy of lymphedema].

Authors:  E Földi
Journal:  Hautarzt       Date:  2012-08       Impact factor: 0.751

Review 2.  Fat Therapeutics: The Clinical Capacity of Adipose-Derived Stem Cells and Exosomes for Human Disease and Tissue Regeneration.

Authors:  Lipi Shukla; Yinan Yuan; Ramin Shayan; David W Greening; Tara Karnezis
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.